$0.765
0.0025[0.33%]
At close: Apr 18
$0.765
0[0.00%]
After Hours: 5:07PM EDT
HOOKIPA Pharma
(NASDAQ:HOOK)HOOKIPA Pharma Stock (NASDAQ:HOOK), Analyst Ratings, Price Targets, Predictions
HOOKIPA Pharma Inc has a consensus price target of $5.03, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, HC Wainwright & Co., and RBC Capital on March 25, 2024, March 25, 2024, and January 30, 2024. With an average price target of $5.5 between RBC Capital, HC Wainwright & Co., and RBC Capital, there's an implied 618.95% upside for HOOKIPA Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
Truist Securities
Morgan Stanley
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for HOOKIPA Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/25/2024 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 553.59% | RBC Capital | Brian Abrahams | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 03/25/2024 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 749.67% | HC Wainwright & Co. | Arthur He | → $6.5 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2024 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 553.59% | RBC Capital | Brian Abrahams | $6 → $5 | Maintains | Outperform | Get Alert |
| 09/27/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 815.03% | RBC Capital | Brian Abrahams | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 09/06/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 422.88% | Truist Securities | Asthika Goonewardene | → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 749.67% | HC Wainwright & Co. | Arthur He | $8 → $6.5 | Maintains | Buy | Get Alert |
| 06/30/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 815.03% | RBC Capital | Brian Abrahams | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 06/05/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 194.12% | Morgan Stanley | Vikram Purohit | $2 → $2.25 | Maintains | Equal-Weight | Get Alert |
| 05/12/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 945.75% | HC Wainwright & Co. | Arthur He | → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 422.88% | Truist Securities | Asthika Goonewardene | $11 → $4 | Maintains | Buy | Get Alert |
| 03/16/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 945.75% | HC Wainwright & Co. | Arthur He | → $8 | Reiterates | → Buy | Get Alert |
| 12/02/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | -34.64% | B of A Securities | Alec Stranahan | $6 → $0.5 | Downgrade | Buy → Underperform | Get Alert |
| 11/15/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 815.03% | RBC Capital | Brian Abrahams | $8 → $7 | Maintains | Outperform | Get Alert |
| 08/23/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 1337.91% | Truist Securities | Asthika Goonewardene | $16 → $11 | Maintains | Buy | Get Alert |
| 08/11/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 292.16% | SVB Leerink | Andrew Berens | $4 → $3 | Maintains | Outperform | Get Alert |
| 03/25/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 1076.47% | RBC Capital | Brian Abrahams | $11 → $9 | Maintains | Outperform | Get Alert |
| 02/17/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 945.75% | HC Wainwright & Co. | Swayampakula Ramakanth | $15 → $8 | Maintains | Buy | Get Alert |
| 02/16/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 422.88% | SVB Leerink | Andrew Berens | $3 → $4 | Maintains | Outperform | Get Alert |
| 11/12/2021 | HOOK | Buy Now | HOOKIPA Pharma | $0.77 | 684.31% | Morgan Stanley | Vikram Purohit | — | Downgrade | Overweight → Equal-Weight | Get Alert |
FAQ
What is the target price for HOOKIPA Pharma (HOOK)?
The latest price target for HOOKIPA Pharma (NASDAQ: HOOK) was reported by RBC Capital on March 25, 2024. The analyst firm set a price target for $5.00 expecting HOOK to rise to within 12 months (a possible 553.59% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for HOOKIPA Pharma (HOOK)?
The latest analyst rating for HOOKIPA Pharma (NASDAQ: HOOK) was provided by RBC Capital, and HOOKIPA Pharma reiterated their outperform rating.
When was the last upgrade for HOOKIPA Pharma (HOOK)?
There is no last upgrade for HOOKIPA Pharma.
When was the last downgrade for HOOKIPA Pharma (HOOK)?
The last downgrade for HOOKIPA Pharma Inc happened on December 2, 2022 when B of A Securities changed their price target from $6 to $0.5 for HOOKIPA Pharma Inc.
When is the next analyst rating going to be posted or updated for HOOKIPA Pharma (HOOK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HOOKIPA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HOOKIPA Pharma was filed on March 25, 2024 so you should expect the next rating to be made available sometime around March 25, 2025.
Is the Analyst Rating HOOKIPA Pharma (HOOK) correct?
While ratings are subjective and will change, the latest HOOKIPA Pharma (HOOK) rating was a reiterated with a price target of $0.00 to $5.00. The current price HOOKIPA Pharma (HOOK) is trading at is $0.77, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.